← Back to Skills Marketplace

Alexion Pharma

Name: Alexion Pharma
Author: hanxueyuan

by hanxueyuan · GitHub ↗ · v1.0.0 · MIT-0

cross-platform ✓ Security Clean

Downloads

Stars

Active Installs

Versions

Install in OpenClaw

/install alexion-pharma

Description

开发全球首款补体C5抑制孤儿药Soliris，专注补体介导罕见病治疗，2021年被阿斯利康以390亿美元收购。

README (SKILL.md)

历史时间线

1992 Leonard Bell博士在康涅狄格创立Alexion
2007 FDA批准Soliris（eculizumab），全球首款补体C5抑制剂
2013 收购Synageva，获得法布瑞病药物
2017 推出第二代Soliris升级版Ultomiris，给药频率从每2周降至每8周
2019 收购Achillion获得补体因子B抑制剂
2021 阿斯利康以390亿美元完成收购
2023 Soliris+Ultomiris全球年销售超50亿美元

商业模式

专注"孤儿药"——患者少于20万的罕见病。Soliris定价年费用超50万美元，但因疗效显著（将PNH从致死性疾病转为可控慢性病），医保和商业保险覆盖率高。被阿斯利康收购后获得全球商业化网络支持，管线扩展到更多补体介导疾病。

护城河分析

补体C5抑制领域近乎垄断。Soliris有15年市场独占期，Ultomiris延长了生命周期。罕见病药物研发门槛高（患者招募困难、临床试验复杂），后来者难以追赶。阿斯利康的收购为其提供了罕见病业务板块的核心资产。

关键数据

Soliris年销售额峰值约30亿美元
Ultomiris年销售额超20亿美元
全球PNH患者约16,000人
被收购价390亿美元（2021）

有趣事实

Soliris被称为"世界上最昂贵的药物"之一，年治疗费用曾高达50万美元以上。但考虑到它治疗的PNH患者在药物出现前平均预期寿命不到10年，这一定价引发了关于孤儿药价值的广泛辩论。

Usage Guidance

From a security perspective, this skill appears low risk. Treat its business and medical facts as general reference material and verify them against current authoritative sources before relying on them for decisions.

Capability Analysis

Type: OpenClaw Skill Name: alexion-pharma Version: 1.0.0 The skill bundle contains purely informational content regarding Alexion Pharmaceuticals, including its history, business model, and acquisition by AstraZeneca. There is no executable code, network activity, or prompt injection attempts in SKILL.md or _meta.json.

Capability Assessment

✓ Purpose & Capability

The skill content is coherent with its stated purpose: a short Chinese-language background brief on Alexion, Soliris, rare-disease drugs, and AstraZeneca's acquisition.

✓ Instruction Scope

The instructions are limited to informational reference material and do not direct the agent to override user goals, run commands, access files, call APIs, or take actions.

✓ Install Mechanism

There is no install specification and no code files; the registry describes it as an instruction-only skill.

✓ Credentials

The skill requires no binaries, environment variables, credentials, config paths, OS access, or external services.

✓ Persistence & Privilege

No persistence, background behavior, delegated authority, account access, or privilege escalation is described in the artifacts.

How to Use

Make sure OpenClaw is installed (local or Docker)
Run the install command in chat: /install alexion-pharma
After installation, invoke the skill by name or use /alexion-pharma
Provide required inputs per the skill's parameter spec and get structured output

Version History

v1.0.0

- 初始发布，详细介绍Alexion Pharmaceuticals的历史发展、核心产品Soliris与Ultomiris、商业模式和被阿斯利康收购历程。 - 提供罕见病药物市场和补体系统靶向疗法的分析信息。 - 总结关键销售数据、并购金额及罕见病药物行业护城河。 - 列出Soliris高定价及其对罕见病治疗行业的影响和讨论。

Metadata

Slug alexion-pharma

Version 1.0.0

License MIT-0

All-time Installs 0

Active Installs 0

Total Versions 1

Frequently Asked Questions

What is Alexion Pharma?

开发全球首款补体C5抑制孤儿药Soliris，专注补体介导罕见病治疗，2021年被阿斯利康以390亿美元收购。 It is an AI Agent Skill for Claude Code / OpenClaw, with 4 downloads so far.

How do I install Alexion Pharma?

Run "/install alexion-pharma" in the OpenClaw or Claude Code chat to install it in one step — no extra setup required.

Is Alexion Pharma free?

Yes, Alexion Pharma is completely free, licensed under MIT-0. You can download, install and use it at no cost.

Which platforms does Alexion Pharma support?

Alexion Pharma is cross-platform and runs anywhere OpenClaw / Claude Code is available (cross-platform).

Who created Alexion Pharma?

It is built and maintained by hanxueyuan (@hanxueyuan); the current version is v1.0.0.

More Skills